A significant challenge in high-throughput screening (HTS) campaigns is the identification of assay technology interference compounds. A Compound Interfering with an Assay Technology (CIAT) gives false readouts in many assays. CIATs are often considered viable hits and investigated in follow-up studies, thus impeding research and wasting resources. In this study, we developed a machine-learning (ML) model to predict CIATs for three assay technologies. The model was trained on known CIATs and non-CIATs (NCIATs) identified in artefact assays and described by their 2D structural descriptors. Usual methods identifying CIATs are based on statistical analysis of historical primary screening data and do not consider experimental assays identifyin...
Complex mixtures containing natural products are still an interesting source of novel drug candidate...
Firefly luciferase is an enzyme that has found ubiquitous use in biological assays in high-throughpu...
Drug discovery is no longer relying on the one gene-one disease paradigm nor on target-based screeni...
Modern high-throughput screening (HTS) is a well-established approach for hit finding in drug discov...
Modern high-throughput screening (HTS) is a well-established approach for hit finding in drug discov...
A major conundrum in High-Throughput Screening stud-ies is the presence of frequent-hitters, which i...
AlphaScreen is one of the most widely used assay technologies in drug discovery due to its versatili...
Scoring the activity of compounds in phenotypic high-throughput assays presents a unique challenge b...
Screening of compound libraries against panels of targets yields profiling matrices. Such matrices t...
Background Tuberculosis is a contagious disease caused by Mycobacterium tuberculosis (Mtb), affecti...
Background Tuberculosis is a contagious disease caused by Mycobacterium tuberculosis (Mtb), affecti...
Assay interference caused by small molecules continues to pose a significant challenge for early dru...
Assay interference caused by small molecules continues to pose a significant challenge for early dru...
Motivation: The comprehensive information of small molecules and their biological activities in PubC...
Firefly luciferase is an enzyme that has found ubiquitous use in biological assays in high-throughpu...
Complex mixtures containing natural products are still an interesting source of novel drug candidate...
Firefly luciferase is an enzyme that has found ubiquitous use in biological assays in high-throughpu...
Drug discovery is no longer relying on the one gene-one disease paradigm nor on target-based screeni...
Modern high-throughput screening (HTS) is a well-established approach for hit finding in drug discov...
Modern high-throughput screening (HTS) is a well-established approach for hit finding in drug discov...
A major conundrum in High-Throughput Screening stud-ies is the presence of frequent-hitters, which i...
AlphaScreen is one of the most widely used assay technologies in drug discovery due to its versatili...
Scoring the activity of compounds in phenotypic high-throughput assays presents a unique challenge b...
Screening of compound libraries against panels of targets yields profiling matrices. Such matrices t...
Background Tuberculosis is a contagious disease caused by Mycobacterium tuberculosis (Mtb), affecti...
Background Tuberculosis is a contagious disease caused by Mycobacterium tuberculosis (Mtb), affecti...
Assay interference caused by small molecules continues to pose a significant challenge for early dru...
Assay interference caused by small molecules continues to pose a significant challenge for early dru...
Motivation: The comprehensive information of small molecules and their biological activities in PubC...
Firefly luciferase is an enzyme that has found ubiquitous use in biological assays in high-throughpu...
Complex mixtures containing natural products are still an interesting source of novel drug candidate...
Firefly luciferase is an enzyme that has found ubiquitous use in biological assays in high-throughpu...
Drug discovery is no longer relying on the one gene-one disease paradigm nor on target-based screeni...